Compounds and methods developed using high throughput screening and cysticidal drug susceptibility assays for treatment or prevention of infections caused by Acanthamoeba species in both the active trophozoite life stage and the dormant cyst life stage (GSU 2018-17)

About

Introduction: Acanthamoeba is a genus of amoebae that are among the most prevalent protozoa found in the environment. Several species of Acanthamoeba have been found to be responsible for the painful, sight-threatening disease of the cornea, Acanthamoeba keratitis. Severe conditions of this disease can require corneal transplants or even enucleation of the eye. Infection with Acanthamoeba keratitis is most commonly associated with contact lens use, particularly when lens wearers carry out improper lens disinfection or hygiene before handling contact lenses. Based on a population-based survey, in 2014, there were ~818,000 Acanthamoeba infections per year associated with contact lens wearers. However, the increasing number of people wearing contact lenses globally is resulting in a corresponding increase in Acanthamoeba infections as well. Some reports estimate a prevalence as high as 1.5 infections per 10,000 soft contact lens wearers annually depending on location. To make matters worse, multipurpose contact lens solutions are generally ineffective against Acanthamoeba. Current therapies are arduous. And because infectious generally involve a mixture of trophozoites and cysts, the therapies are poorly effective due to their inability to kill the protective cyst stage that can persist and cause a recurrent disease. Additionally, current therapeutic compounds have poor selectivity indices and are toxic with prolonged use in required cysticidal concentrations. Therefore, there is a strong need for new therapies against the Acanthamoeba species that exhibit broader, less toxic and more effective activity. Technology: Georgia State University researchers and their collaborators have discovered a potential Acanthamoeba treatment through a novel high-throughput, strain-specific, cysticidal assay. Fully mature cysts obtained by controlling encystation and excystation of each strain in vitro were used to test different compounds for cysticidal activity to find a novel class of diamidines. These diamidine-containing compounds, which are both trophocidal and cysticidal, showed acceptable cytotoxicity with selectivity index values greater than 10.

Key Benefits

Demonstrated cysticidal activity in vitro, with less cytotoxicity and improved selectivity. Can potentially be used either topically as eye drops to treat Acanthamoeba keratitis or as a lens disinfectant to prevent Acanthamoeba infections. Can also be administered systemically or directly to the brain via intrathecal injection, intravenously or orally in form of a liquid or solid such as a pill or tablet, to effectuate treatment of fatal central nervous system infections caused by Acanthamoeba spp. Can potentially also be used in treating infections caused by Balamuthia mandrillaris trophozoites and/or cysts.

Register for free for full unlimited access to all innovation profiles on LEO

  • Discover articles from some of the world’s brightest minds, or share your thoughts and add one yourself
  • Connect with like-minded individuals and forge valuable relationships and collaboration partners
  • Innovate together, promote your expertise, or showcase your innovations